MiR-17-5p Regulates Proliferation and Apoptosis of Uterine Fibroids via Targeting ESR1


Abstract

Background: The treatment of uterine fibroids and the development of new drugs depend on a deeper understanding of the developmental mechanisms of uterine fibroids. Here, the role of ESR1 and miR-17 on the uterine fibroids cell proliferation and apoptosis and their relationship were investigated in USMCs.

Methods: The CCK-8 and EDU experiments explored the effects of ESR1 and MiR-17-5p on the viability and proliferation of USMC cell lines; TUNEL studied the effects of ESR1 and MiR-17-5p on apoptosis of USMC cells, and WB detected ESR1 and MiR-17-5p expression of apoptosis marker gene; luciferase report experiment and WB explore the molecular mechanism of MiR-17-5p inhibiting ESR1 expression and ESR1 promoting TP53 expression, CHIP experiment further explores the molecular mechanism of ESR1 promoting TP53 expression.

Results: Our results showed that ESR1 increased the proliferation of USMCs and inhibited their apoptosis. In addition, ESR1 could directly bind the promoter region of TP53 and inhibit its expression. MiR-17 increased the apoptosis of USMCs and inhibited their proliferation via decreasing the level of ESR1 by targeting its 3’UTR.

Conclusion: Finally, we concluded that MiR-17-5p regulates the proliferation and apoptosis of uterine fibroids by targeting ESR1.

Keywords: MiR-17-5p; Proliferation; Apoptosis; Uterine fibroids; ESR1

Introduction

Uterine fibroids are benign lesions or uterine tumors [1]. At present, the main treatment of uterine fibroids is hysterectomy, which may affect fertility and have a profound impact on health [2]. The development of new uterine fibroids treatments and drugs depends on a deeper understanding of the development of uterine fibroids and the discovery of new therapeutic targets.

Hormone factors synthesized by estrogen are indispensable in the progression of cancer. ESR1 is a transcription factor that responds to estrogen and various growth factors in a variety of tissue types and is activated by ligands, further affecting downstream gene expression, including affecting the mammary gland Proliferation of epithelial tissue [3]. The function of ESR1 in uterine fibroids has not been reported.

MiRNAs can mediate mRNA translational repression or cleavage and down-regulate the protein levels by binding to the complementary site in 3’UTR or mRNA [4-6]. MiR-93 and miR-17 belong to the miR-17-92 family, which share similar binding sites. Previous studies have shown that miR-
93-5p exerts tumor suppressive effects in breast and cervical cancer [7-10]. Whether miR-17 can inhibit the occurrence and development of uterine fibroids is still unclear.

The roles of ESR1 and miR-17 on the proliferation and apoptosis were detected in USMCs in this study. Our data showed that ESRI could promote proliferation and inhibit apoptosis of USMCs, ESRI directly bind the promoter of TP53 to inhibit its expression. MiR-17 increased apoptosis of USMCs and inhibited their proliferation via inhibiting expression of ESRI by targeting its 3’UTR. Our research provides a new understanding of the development of uterine fibroids and provides a theoretical basis for the treatment of uterine fibroids.

Materials and Methods

Cell culture

USMCs were purchased from ATCC (USA). USMCs were cultured in DMEM (Invitrogen, USA) added with 10% FBS (Every Green, China) and incubate in a 37°C incubator with 5% CO2.

Plasmid constructs

To knockdown the endogenous expression of ESRI (NM_001122741), three siRNAs: Si-ESR1-1: 5’-GACTATGCTTCAGGCTACCATTATG-3’, Si-ESR1-2: 5’-GCCTACTGTTGAGTGTCAATGACT-3’, Si-ESR1-3: 5’-GACGGAAGAGGAGGAGAAATGTGTA-3’ were synthesized (Ribobio, China). And random sequence of the same length was synthesized as a NC (Si-NC). The expression vector ESRI could ectopically express ESRI, and the ESRI cDNA fragment was inserted into pCDNA3.1 (Invitrogen, USA). The primer sequence for constructing the recombinant plasmid was as follows: ESRI forward: 5’-GCGGTTACCATGACCATGACCATGACCCCTCCAAGAACC-3’, reverse: 5’-GGCGCTGAGCTGACGGGAGGGAACCTC-3’. For ectopic expression or knock down miR-17-5p (MIMAT0000070), miR-17-5p mimics and miR-17-5p inhibitor were synthesized (Ribobio, China) as well as the corresponding NCS, NC-mimics and NC-inhibitor. The ESRI 3’UTR WT fragment was cloned into dual-luciferase miRNA target expression vector pmirGLO (Invitrogen, USA), the primers used for MUT ESR1 3’UTR (binding site of miR-17-5p was mutated) were as follows: ESR1-3’UTR-WT-luc forward: 5’-CTGAACGACCCCAATCTCAGG-3’, reverse: 5’-CTGTACAGACGGAGATGCTA-3’. Table 1: The primers used for qRT-PCR.

<table>
<thead>
<tr>
<th>Name</th>
<th>Forward(5’-3’)</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCNA</td>
<td>5’-CGTCTGGGTGGAATATTAGCCTCCA-3’</td>
<td>5’-CAGGGTGAGGTCGAGACGC-3’</td>
</tr>
<tr>
<td>K67</td>
<td>5’-GGGCAATTCCTGTCGTTTAAAT-3’</td>
<td>5’-GTTATGGCTTGGGAAACCT-3’</td>
</tr>
<tr>
<td>cyclin D1</td>
<td>5’-GCTCGAGAAGTGGGAACCATC-3’</td>
<td>5’-GCTCTCTTCGACACATTTGGA-3’</td>
</tr>
<tr>
<td>Bcl-2</td>
<td>5’-GTCTTCGTCGGGGAGGATCAT-3’</td>
<td>5’-CATTCCGATATAGGCTGGGAC-3’</td>
</tr>
<tr>
<td>Bcl-xL</td>
<td>5’-TTTGCGAGGCTGTGTTCTAGG-3’</td>
<td>5’-GCCATTTAGTCCTCCAGTG-3’</td>
</tr>
<tr>
<td>Caspase3</td>
<td>5’-CATGGAAGCAGCTCAATGGACT-3’</td>
<td>5’-CTGTACAGACGGAGATGCTA-3’</td>
</tr>
<tr>
<td>TP53</td>
<td>5’-GAAGACCGCAGGCAATCTCGG-3’</td>
<td>5’-CTGTACAGACGGAGATGCTA-3’</td>
</tr>
</tbody>
</table>

Transfection

All the mimics, inhibitor and the plasmids were transfected with Lipofectamine3000 (Invitrogen, USA). Briefly, the p3000 fraction and plasmid were incubated in a certain ratio, then incubated with Lip3000 fraction, and the mixture was added to the cells. For mimics and inhibitors, incubate directly with Lip3000 fraction and add to the guidance of the manufacturer’s instructions.

Cell viability assay

We used the CCK-8 (Beyotime, China) to measure the cell viability. Concisely, 96-well plate was seeded with 2 × 10^4 UMSCs per well. CCK-8 reagent was added to each well 48 h after transfection, and detected the absorbance value at 450 nm using a full-wavelength microplate reader to calculate cell viability under the guidance of the manufacturer’s instructions.

EdU-labeling assay

We used the cell-light TMEdu in vitro cell proliferation imaging kit (Ribobio, China) to detect the cell proliferation. Briefly, 5 × 10^4 UMSCs per well were inoculated onto 14 mm glass slides and incubated overnight, and DNA synthesis was detected 48 h after transfection. Nuclei were labeled with DAPI (Beyotime, China) under the guidance of the manufacturer’s instructions and the proliferation of the cells was evaluated with a confocal laser scanning microscope (OLYMPUS, Japan). Statistical analysis was performed using ImageJ software.

TUNEL assay

We used the TUNEL Apoptosis Detection Kit (Yeasen, China) to detect apoptosis under the guidance of the manufacturer’s instructions. 4 × 10^4 UMSCs per well were inoculated onto 14 mm glass slides and incubated overnight, and apoptosis was measured 48 h after transfection. Nuclei were labeled with DAPI, and apoptosis was evaluated with confocal laser scanning microscope (OLYMPUS, Japan). Statistical analysis was performed using ImageJ software.

RT-PCR and qRT-PCR

We extracted total RNA with Ultrapure RNA Kit (CWBIO, Japan). We used the TUNEL Apoptosis Detection Kit (Yeasen, China) to detect apoptosis under the guidance of the manufacturer’s instructions. The primers used for qRT-PCR.

Table 1: The primers used for qRT-PCR.

<table>
<thead>
<tr>
<th>Name</th>
<th>Forward(5’-3’)</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCNA</td>
<td>5’-GGGCAATTCCTGTCGTTTAAAT-3’</td>
<td>5’-GTTATGGCTTGGGAAACCT-3’</td>
</tr>
<tr>
<td>K67</td>
<td>5’-GGGCAATTCCTGTCGTTTAAAT-3’</td>
<td>5’-GTTATGGCTTGGGAAACCT-3’</td>
</tr>
<tr>
<td>cyclin D1</td>
<td>5’-GCTCGAGAAGTGGGAACCATC-3’</td>
<td>5’-GCTCTCTTCGACACATTTGGA-3’</td>
</tr>
<tr>
<td>Bcl-2</td>
<td>5’-GTCTTCGTCGGGGAGGATCAT-3’</td>
<td>5’-CATTCCGATATAGGCTGGGAC-3’</td>
</tr>
<tr>
<td>Bcl-xL</td>
<td>5’-TTTGCGAGGCTGTGTTCTAGG-3’</td>
<td>5’-GCCATTTAGTCCTCCAGTG-3’</td>
</tr>
<tr>
<td>Caspase3</td>
<td>5’-CATGGAAGCAGCTCAATGGACT-3’</td>
<td>5’-CTGTACAGACGGAGATGCTA-3’</td>
</tr>
<tr>
<td>TP53</td>
<td>5’-GAAGACCGCAGGCAATCTCGG-3’</td>
<td>5’-CTGTACAGACGGAGATGCTA-3’</td>
</tr>
</tbody>
</table>

Kun Li, et al., Clinics in Oncology - General Oncology

China), and 1 μg RNA was used to synthesize cDNA with HiScript II Q RT SuperMix for qPCR (+gDNA wiper) (Vazyme, China). QRT-PCR was performed with Hieff qPCR SYBR Green Master Mix (Yeasen, China) using CFX96 system (Bio-Rad, USA). The qRT-PCR primer sequences were available in Table 1. GAPDH was detected to homogenize samples.

**WB assay**

For WB, firstly lyses UMSCs with RIPA lysis buffer (Beyotime, China). Then separated 30 μg total proteins according to the molecular weight by SDS-PAGE, and then transferred to a PVDF membrane. After blocking the non-specific binding on the membrane with skim milk powder, incubated the membranes with the primary antibody for about 12 h at 4°C. All antibodies were as follows: Anti-GAPDH (sc-47724; Santacruz), Anti-CCND1 (ab68153; Abcam), Anti-Bcl-xl (2764; CST), Anti-Bcl2 (2872; CST), Anti-caspase-3 (ab13585; Abcam), Anti-PCNA (ab29; Abcam), Anti-Ki67 (ab197234; Abcam), Anti-p53 (ab1101; Abcam). The membrane was then incubated with a secondary antibody conjugated with HRP (Thermo Fisher, USA) for 1 hour at room temperature. Finally, the substrate (Thermo Fisher, USA) of the conjugated HRP was applied to the surface of the PVDF membrane and detected the chemiluminescence signal. GAPDH was detected to homogenize the sample.

**Luciferase assay**

Luciferase assays were performed used aBio-Glo™ Luciferase Assay System (Promega, USA) according to guidance of the manufacturer’s instructions. 5 × 10^4 UMSCs per well were seeded in 24-well plates to detect the luciferase activity 48 h after transfection. Then measured the protein content using an Enhanced BCA Protein Assay Kit (Beyotime, China) using CFX96 system (Bio-Rad, USA). The relative luciferase activity was characterized using the fluorescence value divided by the protein content.

**ChIP assay**

We used SimpleChIP® Enzymatic Chromatin IP Kit (CST) to measure the binding of the ESR1 and TP53 promoters under the guidance of the manufacturer’s instructions. The DNA-protein complex was incubated with an anti-flag antibody (proteintech). The nucleic acid immunoprecipitated with the flag antibody was recovered, and the TP53 promoter fragment was detected by real-time PCR. The primers used as were as follows: forward 5’-CCAGTCCTTACCATTTCTGC-3’, reverse 5’-GAGGCAGGCTCAGCCCTAGC-3’.

**Statistical analysis**

Each experiment was repeated at least three times independently, and the data was expressed as mean ± SEM. Data were statistically analyzed by two-way ANOVA or by t-test. The significance level was characterized by the probability P<0.05 and P<0.01. (*indicates P<0.05, and ** indicates P<0.01).

**Results**

**ESR1 promoted the proliferation of UMSC**

To explore whether ESR1 affects the proliferation of uterine fibroids, we over expressed or knock down ESR1 in uterine smooth muscle UMSCs. We constructed a plasmid vector capable of over expressing ESR1 and transfected into UMSCs, transfected with pCDNA3.1 vector plasmid was a control group. The CCK-8 assays showed the cell viability of the UMSC cells was significantly promoted with the ectopic expression of ESR1 (Figure 1A), while the viability of the UMSC cells was decreased with the knockdown of endogenous ESR1 by siRNA (Figure 1B). EdU-labeling assays indicated that ectopic expression of ESR1 accelerated division of USMCs (Figure 1C), while ESR1 knockdown decreased the proliferation of UMSC (Figure 1D). Detecting the expression of proliferation marker genes with qRT-PCR and WB, data indicated that the proliferating marker genes PCNA, Ki67 and CCND1 was up-regulated after over expression ESR1 (Figure 1E and 1F), while the expression level of PCNA, Ki67 and CCND1 decreased with the knockdown of ESR1 (Figure 1G and 1H).

**ESR1 inhibited apoptosis in UMSC**

We also explored the effect of ESR1 on the apoptosis of USMC by TUNEL. The results were showed in Figure 2A and 2B, the result showed that over expression of ESR1 remarkably inhibited the apoptosis compared to the control group, and knockdown of endogenous ESR1 increased the apoptosis of USMCs. We checked the levels of Bcl-2, Bcl-xl and Cleaved-Caspase-3. The results showed that ectopic expression of ESR1 decreased the Cleaved-Caspase-3 and increased Bcl-2, Bcl-xl (Figure 2C and 2D), and knockdown of endogenous ESR1 increased the Cleaved-Caspase-3 and decreased...
Bcl-2, Bcl-xL (Figure 2D and 2F). In summary, all results indicated that ESR1 inhibited apoptosis in UMSCs.

**MiR-17-5p inhibited UMSCs’ proliferation**

To explore whether MiR-17-5p affects the proliferation of uterine fibroids, miR-17-5p-mimics and miR-17-5p-inhibitor were transfected into UMSCs. CCK-8 assay revealed that the cell viability of UMSCs was down-regulated as the transfection number of miR-17-5p mimics increased (Figure 3A); the viability of the UMSCs was promoted after transfection miR-17-5p-inhibitor (Figure 3B). EdU-labeling assays indicated that transfected of miR-17-5p-mimics inhibited USMCs’ proliferation (Figure 3C), and inhibition of endogenous miR-17-5p promoted USMCs’ proliferation (Figure 3D). Detection of expression of proliferation marker genes showed PCNA, Ki67 and CCND1 were down-regulated with the transfection of miR-17-5p-mimics in both mRNA and protein level (Figure 3E and 3G), while the expression level of PCNA, Ki67 and CCND1 up-regulated with the inhibition of endogenous miR-17-5p (Figure 3F and 3H).

**MiR-17-5p promoted USMCs’ apoptosis**

We also explored whether miR-17-5p affects USMCs’ apoptosis via TUNEL. The data indicated that transfection of miR-17-5p remarkably promoted the apoptosis progression, and inhibition of endogenous miR-17-5p decreased the apoptosis of USMCs. We checked the expression of Bcl-2, Bcl-xL and Cleaved-Caspase-3. The results showed that transfection of miR-17-5p increased the Cleaved-Caspase-3 and decreased Bcl-2, Bcl-xL (Figure 4C and 4E), and inhibition of endogenous miR-17-5p decreased the Cleaved-Caspase-3 and increased the expression of Bcl-2, Bcl-xL (Figure 4D and 4F). All results indicated that miR-17-5p promoted apoptosis in USMCs.

**MiR-17-5p antagonizes the role of ESR1 in promoting proliferation and inhibiting apoptosis**

To explore the relationship between ESR1 and miR-17-5p on the effect of proliferation and apoptosis in USMCs, we transfected miR-17-5p mimics while over expressing ESR1. Cell proliferation was detected by CCK-8 assays and EdU-labeling assays, and apoptosis was detected by TUNEL. The results showed that the transfection of miR-17-5p mimic could partially inhibit ESR1-promoted USMCs ability and proliferation (Figure 5A and 5B). Similarly, the transfection of miR-17-5p mimic could also antagonize ESR1-mediated USMCs apoptosis (Figure 5C). We checked the expression of PCNA, Ki67, CCND1, Bcl-2, and Cleaved-Caspase-3. Our data showed that the transfection of miR-17-5p mimic could also antagonize ESR1-mediated expression of proliferation and apoptosis relative gene (Figure 5D and 5E).
MiR-17-5p binds to 3'UTR of ESR1

To explore how miR-17-5p affects the expression of ESR1, we used targets can website to predict the 3′UTR of ESR1. The analysis showed there was a miR-17-5p specific site (Figure 6A). To explore whether miR-17-5p binds to ESR1's 3′UTR, two luciferase vectors containing either the WT ESR1 3′UTR (ESR1-3′UTR-WT-luc) or the MUT ESR1 3′UTR (ESR1-3′UTR-M-luc) were constructed (Figure 6B and 6C). Then co-transfected ESR1-3′UTR-WT-luc or ESR1-3′UTR-M-luc with miR-17-5p-mimic or NC-mimic. We found that the miR-17-5p mimic could down-regulate the activity of the ESR1 WT luciferase vector while didn’t affect the activity of MUT vector (Figure 6D). And miR-17-5p mimic decreased the expression of ESR1, and miR-17-5p inhibitor increased the expression of ESR1 (Figure 6E). Together, all results showed that miR-17-5p inhibited ESR1 expression in UMSCs by targeting ESR1 3′UTR.

ESR1 targeted the promoter of TP53

To address how ESR1 affect apoptosis, we first checked the expression of TP53 after ectopic expression of ESR1 in USMCs. Our result showed that ectopic expression of ESR1 down-regulated TP53 and knockdown of ESR1 up-regulated TP53 (Figures 7A-7D). To further confirm the mechanism of the inhibition effect of ESR1 on TP53, we checked ESR1 binding region in TP53 promoter. Bioinformatics analysis unveiled an ESR1 site on TP53 promoter. The wild-type TP53 promoter (TP53-WT-luc) and the MUT TP53 promoter (containing the mutant ESR1 binding sites) (TP53-M-luc) were cloned into pGL3 vector (Figure 7E). Either the luciferase vectors TP53-WT-luc or the TP53-M-luc were co-transfected with miR-17-5p-mimics or NC-mimics and Si-ESR1 or Si-NC to USMC cells for 48 h. (A) Testing the cell viabilities of with MTT assays after transfection. (B) Cell proliferation of USMC cells were detected with EdU assay. (C) Cell apoptosis of USMC cells were detected by TUNEL assays after transfection. (D) Testing mRNA level after transfection and GAPDH was detected to homogenize samples. (E) The protein level in USMC cells was detected after transfection, and GAPDH is detected to homogenize samples.

Discussion

Uterine fibroids are benign lesions or uterine tumors [1]. At present, the main treatment of uterine fibroids is hysterectomy, which may affect fertility and have a profound impact on health [2]. The development of new uterine fibroids treatments and drugs depends on a deeper understanding of the development of uterine fibroids and the discovery of new therapeutic targets.
Tumor cells were uncontrolled proliferative state [11]. Previous research showed that ESR1 was linked to proliferation of breast cancer [12]. Here, our data showed that expression of the proliferating marker genes PCNA, Ki67 and CCND1 was increased in the over expressed ESR1 group in USMC cells (Figure 1G).

We also reported that ESR1 inhibited apoptosis in UMSc (Figure 2A), ectopic expression of ESR1 decreased the Cleaved-Caspase-3 and up-regulated Bcl-2, Bcl-xl (Figure 2C and 2E), and knockdown of endogenous ESR1 increased the Cleaved-Caspase-3 and decreased Bcl-xl, Bcl-2 (Figure 2D and 2F). In addition, ESR1 bound to promoter of TP53 and inhibit TP53 expression (Figure 7).

MiR-17-5p was reported to have important role in breast cancer [5,7,8,13]. Here, we reported that miR-17-5p had an effect of inhibiting proliferation and promoting apoptosis in USMCs (Figure 3 and 4).

MiRNAs negative regulation of target genes via binding to mRNA or 3'UTR to inhibit the expression of target genes [6,14,15]. Here, miR-17-5p was proved to target 3'UTR of ESR1 to inhibit its expression and antagonize its function (Figure 6).

References
